Current Device Needs for Patients with Pediatric and Congenital Heart Disease

Heather M Giacone1, Anne M Dubin1

  • 1Department of Pediatric Cardiology, Lucile Packard Children's Hospital at Stanford University, 750 Welch Road, Palo Alto, CA 94304, USA.

PubMed

Insights

Pediatric electrophysiologists lack specialized cardiac implantable electronic devices (CIEDs) for children, leading to higher complication rates. Improved regulations and clinical trial support are emerging for pediatric and congenital heart disease patients needing CIEDs.

Area of Science:

  • Pediatric Cardiology
  • Biomedical Engineering
  • Medical Device Regulation

Background:

  • Pediatric electrophysiologists face a shortage of cardiac implantable electronic devices (CIEDs) specifically designed for children.
  • Unique pediatric patient characteristics, including vascular and anatomical differences and growth potential, restrict available CIED options.
  • Pediatric and congenital heart disease (CHD) patients experience higher rates of CIED-related complications than adult populations.

Purpose of the Study:

  • To highlight the challenges in pediatric CIED implantation.
  • To emphasize the need for pediatric-specific device development and advocacy.
  • To discuss the progress in regulatory improvements and clinical trial support for pediatric CIEDs.

Main Methods:

  • Literature review and expert opinion synthesis regarding pediatric CIED challenges.
  • Analysis of patient-specific factors influencing device selection and outcomes.
  • Examination of collaborative efforts between regulatory bodies, industry, and medical societies.

Main Results:

  • A significant deficit in pediatric-appropriate CIEDs exists, impacting patient care.
  • Pediatric and CHD patients exhibit increased risks for CIED-related complications.
  • Collaborative initiatives have enhanced regulatory frameworks and facilitated clinical trials for pediatric devices.

Conclusions:

  • Addressing the paucity of pediatric CIEDs is crucial for improving patient outcomes.
  • Continued collaboration is essential for advancing device innovation and ensuring patient safety.
  • Regulatory advancements and trial support are vital for meeting the growing needs of pediatric patients requiring CIEDs.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
15
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
30
Cardiac Catheterization IV: Nursing Management01:26

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...
31